S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:TCDATricida Stock Price, Forecast & News

$13.30
-0.37 (-2.71 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$13.13
Now: $13.30
$13.74
50-Day Range
$13.27
MA: $20.35
$27.48
52-Week Range
$12.91
Now: $13.30
$44.30
Volume591,700 shs
Average Volume436,518 shs
Market Capitalization$665.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California.
Read More
Tricida logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TCDA
CUSIPN/A
CIKN/A
Phone415-429-7800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$5.32 per share

Profitability

Net Income$-176,810,000.00

Miscellaneous

Employees76
Market Cap$665.65 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$13.30
-0.37 (-2.71 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for TCDA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tricida (NASDAQ:TCDA) Frequently Asked Questions

How has Tricida's stock price been impacted by Coronavirus?

Tricida's stock was trading at $28.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TCDA shares have decreased by 52.6% and is now trading at $13.30.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Tricida?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Tricida
.

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Tricida
.

How were Tricida's earnings last quarter?

Tricida Inc (NASDAQ:TCDA) issued its quarterly earnings data on Wednesday, August, 5th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($1.46) by $0.30.
View Tricida's earnings history
.

What price target have analysts set for TCDA?

2 equities research analysts have issued 12-month price targets for Tricida's stock. Their forecasts range from $40.00 to $44.00. On average, they anticipate Tricida's stock price to reach $42.00 in the next year. This suggests a possible upside of 215.8% from the stock's current price.
View analysts' price targets for Tricida
.

Has Tricida been receiving favorable news coverage?

Media coverage about TCDA stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tricida earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Tricida
.

Who are some of Tricida's key competitors?

What other stocks do shareholders of Tricida own?

Who are Tricida's key executives?

Tricida's management team includes the following people:
  • Dr. Gerrit Klaerner, Founder, Pres, CEO & Exec. Director (Age 48)
  • Mr. Geoffrey M. Parker, CFO & Sr. VP (Age 54)
  • Dr. Dawn Parsell Ph.D., Sr. VP of Clinical Devel. (Age 57)
  • Steffen Pietzke, VP of Fin. & Chief Accounting Officer
  • Dr. Wilhelm Stahl, CTO & Sr. VP (Age 59)

When did Tricida IPO?

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen acted as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by a number of retail and institutional investors. Top institutional investors include New York State Common Retirement Fund (0.46%), Candriam Luxembourg S.C.A. (0.38%), Bank of New York Mellon Corp (0.23%), Barclays PLC (0.14%), Swiss National Bank (0.13%) and UBS Group AG (0.12%). Company insiders that own Tricida stock include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl.
View institutional ownership trends for Tricida
.

Which institutional investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., and California Public Employees Retirement System. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, and Wilhelm Stahl.
View insider buying and selling activity for Tricida
.

Which institutional investors are buying Tricida stock?

TCDA stock was purchased by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, SG Americas Securities LLC, Barclays PLC, Russell Investments Group Ltd., Swiss National Bank, Aigen Investment Management LP, Bank of New York Mellon Corp, and Trexquant Investment LP. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Orbimed Advisors Llc.
View insider buying and selling activity for Tricida
.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $13.30.

How big of a company is Tricida?

Tricida has a market capitalization of $665.65 million. The company earns $-176,810,000.00 in net income (profit) each year or ($3.72) on an earnings per share basis. Tricida employs 76 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.